Quasense Information

What's inside Quasense

Recent Quasense Side Effects

Posted by crancran18 18 days ago
I am really sorry for everyone out there that had bad experiences with Quasense. I had been taking this pill for 9 months and...

Posted by jprince 20 days ago
Wow! I thought something was wrong with me but seems like its this wonderful pill instead. I've been spotting for the whole e...

Posted by funsized88 26 days ago
It takes about two of the three-month cycles to stop the breakthrough bleeding. After that it is super nice not to have your ...

Quasense in the News

Business wire briefs -- 12/15 - Press-Enterprise
Watson began selling Quasense, its version of Seasonale, 15 months ago. Sandoz is seeking US Food and Drug Administration permission to sell a copy. ...
Fri Dec 14 22:19:38 -0500 2007

Watson confirms Duramed's lawsuit for Seasonale - Trading Markets (press release)
The lawsuit asserts that Watson's Quasense product infringes Duramed's US patent number 5895032. Watson launched its Quasense product in September 2006 ...
Tue Dec 18 05:33:59 -0500 2007

Barr Sues Watson, Sandoz Over Patent - Forbes
In September 2006, Watson launched Quasense, a generic version of Seasonale, after final approval from the US Food & Drug Administration, according to Barr. ...
Fri Dec 14 15:34:50 -0500 2007

Quasense Chemical Information

ethinyl estradiol - A semisynthetic estrogen. Ethinyl estradiol binds to the estrogen receptor complex and enters the nucleus, activating DNA transcription of genes involved in estrogenic cellular responses. This agent also inhibits 5-alpha reductase in epididymal tissue, which lowers testosterone levels and may delay progression of prostatic cancer. In addition to its antineoplastic effects, ethinyl estradiol protects against osteoporosis. In animal models, short-term therapy with this agent has been shown to provide long-term protection against breast cancer, mimicking the antitumor effects of pregnancy. (NCI04)

levonorgestrel - The levorotatory form of norgestrel and synthetic progestogen with progestational and androgenic activity. Levonorgestrel binds to the progesterone receptor in the nucleus of target cells, thereby stimulating the resulting hormone-receptor complex, initiating transcription, and increasing the synthesis of certain proteins. This results in a suppression of luteinizing hormone (LH) activity and an inhibition of ovulation, as well as an alteration in the cervical mucus and endometrium.